1. A 54-year-old man with WHO Group 1 PAH and concurrent atrial fibrillation is maintained on bosentan 125 mg twice daily and warfarin. His INR has been consistently between 1.3 and 1.5 over the past three months despite a warfarin dose that previously produced an INR of 2.4. He reports no missed doses of either drug. Which explanation and management response are correct?
A) Bosentan inhibits vitamin K epoxide reductase, directly impairing warfarin's anticoagulant mechanism at its site of action; the correct response is to switch from warfarin to a direct oral anticoagulant (DOAC) that bypasses vitamin K metabolism
B) Bosentan induces CYP2C9, the principal enzyme responsible for S-warfarin metabolism, accelerating warfarin clearance and reducing its plasma concentration; the appropriate response is to increase the warfarin dose with close INR monitoring to re-establish the therapeutic range, while continuing bosentan at its current PAH dose
C) The subtherapeutic INR reflects dietary vitamin K excess rather than a drug interaction; bosentan has no effect on CYP enzymes and the warfarin dose should not be changed until a 3-day dietary recall confirms consistent vitamin K intake
D) Bosentan induces CYP3A4, which metabolizes the R-enantiomer of warfarin; because the R-enantiomer contributes minimally to anticoagulant effect, the interaction is clinically insignificant and no warfarin dose adjustment is required
E) Bosentan competitively displaces warfarin from albumin binding sites, increasing the free warfarin fraction and paradoxically raising anticoagulant activity; the subtherapeutic INR suggests the patient is non-adherent to warfarin rather than experiencing a drug interaction
ANSWER: B
Rationale:
Bosentan is a potent inducer of CYP2C9, the cytochrome P450 isoform responsible for metabolizing the pharmacologically active S-enantiomer of warfarin. Induction of CYP2C9 accelerates hepatic S-warfarin clearance, reducing plasma warfarin concentrations and lowering anticoagulant effect, which manifests as a falling INR in a previously stable patient. The appropriate clinical response is to increase the warfarin dose under close INR guidance — typically checking INR weekly during the dose-adjustment period — until the therapeutic range of 2.0 to 3.0 is re-established. Bosentan should not be discontinued for this reason, as it is essential PAH therapy; the interaction is manageable with dose adjustment.
Option A: Option A is incorrect because bosentan does not inhibit vitamin K epoxide reductase; that is warfarin's own mechanism of action, not a bosentan interaction target. While DOACs are a reasonable consideration in some PAH patients, the clinical question here is identifying the mechanism of the subtherapeutic INR, and the mechanism is CYP2C9 induction, not vitamin K pathway interference.
Option C: Option C is incorrect because bosentan has well-established CYP2C9 and CYP3A4 induction effects and its warfarin interaction is clinically significant and documented; attributing the INR change to dietary vitamin K without investigating the known drug interaction is inappropriate in a patient who recently started a potent CYP inducer.
Option D: Option D is incorrect because bosentan induces both CYP3A4 and CYP2C9, and the warfarin interaction is primarily mediated through CYP2C9 acting on the S-enantiomer — the pharmacologically dominant enantiomer responsible for the majority of anticoagulant effect; dismissing the interaction as clinically insignificant is incorrect and potentially dangerous.
Option E: Option E is incorrect because protein displacement causing transient INR elevation is the opposite of the observed subtherapeutic INR, and bosentan's warfarin interaction is a hepatic enzyme induction effect rather than a protein binding displacement; non-adherence is contradicted by the patient's report and the consistent pattern of INR below target.
2. A 61-year-old man with PAH maintained on sildenafil 20 mg three times daily develops exertional chest pain. Coronary angiography confirms a non-obstructive lesion with microvascular angina. His cardiologist proposes adding isosorbide mononitrate 30 mg daily for symptom control. Which response to this proposal is correct?
A) Isosorbide mononitrate can be added safely at half the standard dose because sildenafil's pulmonary selectivity at PAH doses limits the degree of systemic vasodilation; a baseline blood pressure check before each nitrate dose is sufficient precaution
B) Isosorbide mononitrate is safe in this patient because organic nitrates raise cGMP only in venous smooth muscle while sildenafil acts only on pulmonary arterial PDE-5; there is no pharmacodynamic overlap between the two mechanisms
C) Isosorbide mononitrate can be used intermittently as a sublingual rescue agent but not as a long-acting oral formulation; the sublingual route limits systemic absorption enough to avoid the hypotensive interaction with sildenafil
D) Isosorbide mononitrate is absolutely contraindicated in any patient on sildenafil regardless of dose or formulation; nitrates of all types donate nitric oxide (NO) that raises cGMP via soluble guanylate cyclase (sGC), and when combined with PDE-5 inhibition the additive cGMP accumulation causes severe, potentially fatal hypotension; alternative antianginal agents such as beta-blockers or calcium channel blockers should be used instead
E) Isosorbide mononitrate can be added if sildenafil is temporarily held for 12 hours before each nitrate dose; this intermittent sildenafil holiday is sufficient to prevent the hypotensive interaction
ANSWER: D
Rationale:
The combination of sildenafil with nitrates of any formulation is absolutely contraindicated. Organic nitrates such as isosorbide mononitrate undergo enzymatic conversion to release nitric oxide (NO), which activates soluble guanylate cyclase (sGC) in vascular smooth muscle to generate cGMP. Sildenafil inhibits phosphodiesterase-5 (PDE-5), blocking cGMP degradation. When both mechanisms are active simultaneously, cGMP accumulates to levels that produce severe systemic vasodilation, marked hypotension, and cardiovascular collapse that can be fatal. This contraindication applies to all nitrate formulations — oral, sublingual, transdermal, and spray — and all sildenafil doses including the 20 mg PAH dose. For the patient's microvascular angina, alternative antianginal agents that do not interact with PDE-5 inhibitors should be selected: beta-blockers reduce myocardial oxygen demand and are appropriate, and non-dihydropyridine calcium channel blockers (diltiazem, verapamil) can provide antianginal benefit, though the latter must be used with caution in PAH given their negative inotropic and chronotropic effects on the right ventricle.
Option A: Option A is incorrect because the contraindication is absolute and dose-independent; pulmonary selectivity of sildenafil at PAH doses does not eliminate systemic PDE-5 inhibition, and a blood pressure check does not mitigate the risk of the interaction.
Option B: Option B is incorrect because organic nitrates raise cGMP in both venous and arterial vascular smooth muscle through sGC activation, and sildenafil inhibits PDE-5 systemically, not exclusively in the pulmonary circulation; the pharmacodynamic interaction is real and dangerous.
Option C: Option C is incorrect because sublingual nitrates are also absolutely contraindicated with sildenafil; the sublingual route produces rapid and substantial systemic NO release and cGMP accumulation, and the interaction occurs regardless of route or duration of nitrate action.
Option E: Option E is incorrect because a 12-hour sildenafil hold is insufficient; sildenafil has a half-life of approximately 4 hours but active metabolite accumulation and residual PDE-5 inhibition persist longer, and structured guidelines do not endorse a sildenafil holiday strategy as a safe approach to nitrate co-administration.
3. A 38-year-old woman with severe idiopathic PAH on continuous IV epoprostenol presents to the emergency department accompanied by her husband. The infusion pump alarmed approximately 45 minutes ago; she disconnected the line while troubleshooting but could not reconnect it. She now has a respiratory rate of 32 breaths per minute, oxygen saturation of 84% on room air, blood pressure of 78/46 mmHg, and is in marked distress. Her husband has brought the backup pump cassette and the patient's emergency card indicating her current epoprostenol dose. What is the single most critical immediate intervention?
A) Immediately reconnect IV epoprostenol at the patient's established dose using the backup cassette; if IV reconnection cannot be accomplished within minutes, bridge with inhaled iloprost (a prostacyclin analogue available in most centers) until the infusion is restored; this is a life-threatening rebound PAH crisis caused by abrupt loss of pulmonary vasodilation
B) Administer intravenous morphine 4 mg for dyspnea relief and supplemental oxygen at 15 L/min by non-rebreather mask, then arrange urgent transfer to the cardiac catheterization laboratory for emergent right heart catheterization to guide further management
C) Initiate oral sildenafil 20 mg immediately as a bridge because its onset of action within 30 to 60 minutes will partially restore pulmonary vasodilation while IV access is re-established
D) Administer intravenous norepinephrine to support systemic blood pressure and afterload, which will secondarily reduce right ventricular wall stress and buy time for the pulmonary hypertension team to arrange re-initiation of epoprostenol on the following day
E) Obtain an urgent echocardiogram to assess right ventricular function before restarting epoprostenol, as the rebound crisis may have caused irreversible right ventricular failure that would render epoprostenol re-initiation unsafe
ANSWER: A
Rationale:
This patient is in acute rebound PAH crisis — a life-threatening emergency produced by the abrupt loss of continuous IV epoprostenol, which has a plasma half-life of approximately 2 to 5 minutes at physiological pH. Within minutes of infusion interruption, pulmonary vasodilation is eliminated, pulmonary vascular resistance rises acutely, the right ventricle fails against the sudden increase in afterload, systemic output falls, and hypotension ensues. Death can occur within minutes if prostacyclin delivery is not restored. The single most critical intervention is immediate reconnection of IV epoprostenol at the established dose; the patient's backup cassette and documented dose make this feasible. If IV reconnection cannot be accomplished within minutes at the bedside, inhaled iloprost serves as a bridge prostacyclin analogue that can be administered immediately to partially restore pulmonary vasodilation while IV access is restored. Emergency department staff must be educated that delay in restarting epoprostenol is lethal.
Option B: Option B is incorrect because morphine and supplemental oxygen, while supportive, do not address the fundamental problem — absent pulmonary vasodilation from epoprostenol loss; arranging catheterization delays the definitive intervention and will not prevent rapid deterioration.
Option C: Option C is incorrect because oral sildenafil has an onset of action of 30 to 60 minutes and does not provide the rapid, potent pulmonary vasodilation needed to reverse acute rebound crisis; it acts through a completely different mechanism and cannot substitute for the abrupt loss of high-dose prostacyclin infusion.
Option D: Option D is incorrect because vasopressors address systemic hypotension but do not restore pulmonary vasodilation; right ventricular afterload remains critically elevated without prostacyclin, and arranging restart for the following day allows fatal deterioration to proceed.
Option E: Option E is incorrect because performing echocardiography before restarting epoprostenol wastes critical time; right ventricular failure in this context is secondary to the acute loss of prostacyclin and is expected — the treatment is restoring the infusion, not characterizing the degree of RV dysfunction before acting.
4. A 32-year-old woman with newly diagnosed WHO Group 1 PAH is to begin ambrisentan as part of upfront dual oral combination therapy. She is in a stable relationship, uses no contraception currently, and states she may wish to have children in the future. Which counseling and safety requirements must be communicated and confirmed before the first dose is dispensed?
A) She should be counseled that ambrisentan is classified as pregnancy category C and that a single reliable form of contraception is sufficient; pregnancy testing is recommended at baseline and at 6-month intervals; she may consider a brief treatment holiday if she wishes to attempt conception
B) She should be counseled that ambrisentan is safe in the first trimester and that the teratogenicity concern applies only to the second and third trimesters; contraception is therefore required only after the first missed menstrual period
C) She should be counseled that ambrisentan requires no formal pregnancy precautions because its ERA mechanism does not cross the placenta at therapeutic doses; annual gynecological review is sufficient
D) She should be counseled that ambrisentan is absolutely contraindicated in pregnancy; she must use two reliable forms of contraception, beginning before the first dose and continuing throughout therapy; pregnancy testing is performed at baseline and then monthly under the REMS program; if pregnancy occurs, ambrisentan must be stopped immediately and obstetric consultation obtained; she should be clearly informed that planning a pregnancy while on ERA therapy is not a clinical option
E) She should be counseled that ambrisentan is absolutely contraindicated in pregnancy due to severe teratogenicity demonstrated in animal studies at sub-therapeutic doses; two reliable forms of contraception are required throughout therapy and for one month after discontinuation; monthly pregnancy testing is mandatory under the ambrisentan REMS program; a positive test requires immediate discontinuation and urgent obstetric consultation; the desire for future pregnancy must be discussed with her PAH specialist to plan a potential treatment transition timeline well in advance of any attempt to conceive
ANSWER: E
Rationale:
Ambrisentan, like all endothelin receptor antagonists, is absolutely contraindicated in pregnancy based on severe teratogenicity demonstrated in animal studies at doses below the human therapeutic range. The required safety measures are comprehensive and non-negotiable: two reliable forms of contraception must be used — not one — beginning before the first dose is dispensed and continuing throughout therapy and for one month after discontinuation, to cover the pharmacological elimination period. Monthly pregnancy testing is mandated under the ambrisentan REMS program; this is not annual or quarterly but monthly without exception. A positive pregnancy test requires immediate ERA discontinuation and urgent obstetric consultation; there is no dose adjustment or monitoring strategy that permits continuation. In this patient who may wish to conceive in the future, additional counseling is essential: she must understand that planning a pregnancy while on ERA therapy requires a structured transition discussion with her PAH specialist well in advance — typically including a conversation about disease severity, alternative therapeutic options that may be safer in pregnancy, and the significant risks that PAH itself poses during pregnancy independent of drug effects.
Option A: Option A is incorrect because a single form of contraception does not meet the requirement, six-monthly testing does not meet the monthly REMS requirement, and a treatment holiday for conception is not a sanctioned approach without careful specialist-led planning.
Option B: Option B is incorrect because the teratogenicity contraindication is absolute across all trimesters; there is no safe trimester for ERA exposure, and waiting for a missed period before implementing contraception is clinically unacceptable.
Option C: Option C is incorrect because ambrisentan does have formal pregnancy precautions mandated by REMS; it does cross biologically relevant barriers during organogenesis, and annual gynecological review alone is wholly insufficient.
Option D: Option D is incorrect because it omits the one-month post-discontinuation contraception requirement, does not address the future conception counseling imperative, and incompletely conveys the REMS monitoring structure and urgency of obstetric consultation.
5. A 47-year-old woman with idiopathic PAH was started on ambrisentan plus tadalafil four months ago. At reassessment she reports feeling "somewhat better" than at diagnosis. Objective data: WHO-FC III, 6MWD 290 meters, NT-proBNP 620 ng/L, echocardiography shows persistent right ventricular dilation, right atrial pressure 11 mmHg, cardiac index 2.1 L/min/m². She is adherent to both medications. Applying the 2022 ESC/ERS three-strata risk model and treatment targets, what is the appropriate next step?
A) Continue current dual oral combination unchanged because the patient reports subjective improvement, which is the primary indicator of adequate treatment response at 4-month reassessment
B) Discontinue tadalafil and switch to riociguat because the suboptimal response indicates PDE-5 inhibitor failure and the riociguat-ERA combination may be more effective; no washout is required when switching between these agents
C) Escalate therapy by adding a third pathway agent — an inhaled or subcutaneous prostacyclin analogue or selexipag — because this patient has not achieved low-risk status at 4-month reassessment; persistent intermediate risk on dual combination therapy is operationally defined as a treatment failure requiring escalation regardless of subjective improvement
D) Reduce the ambrisentan dose and add spironolactone for right ventricular volume management; pharmacological de-escalation combined with diuresis often restores the hemodynamic profile to low-risk status within an additional 6 months
E) Repeat right heart catheterization before making any treatment change; the 2022 ESC/ERS guidelines require invasive hemodynamic confirmation of persistent intermediate risk before escalation is permitted
ANSWER: C
Rationale:
Applying the 2022 ESC/ERS three-strata risk model to this patient's 4-month data: WHO-FC III places her at intermediate risk; 6MWD of 290 meters (between 165 and 440 meters) is intermediate risk; NT-proBNP of 620 ng/L exceeds the low-risk threshold of below 300 ng/L; echocardiographic RV dilation is an intermediate-to-high-risk echocardiographic finding; right atrial pressure of 11 mmHg and cardiac index of 2.1 L/min/m² are at the intermediate range. The composite profile confirms intermediate risk — not low risk. The 2022 ESC/ERS treatment algorithm is explicit: the treatment target is achieving low-risk status, not merely stabilization or subjective improvement. A patient who remains at intermediate risk after 3 to 6 months of dual oral combination therapy has not met the treatment target, and persistent intermediate risk constitutes a treatment failure requiring escalation to a third pathway agent. Options include adding an inhaled or subcutaneous prostacyclin analogue or selexipag. Subjective improvement does not override objective risk stratification.
Option A: Option A is incorrect because subjective symptom report is not the primary or sufficient endpoint; the 2022 ESC/ERS model requires objective composite risk assessment, and this patient fails to achieve low-risk status by every objective parameter.
Option B: Option B is incorrect because switching from tadalafil to riociguat abandons the dual-combination framework in favor of a different two-drug regimen without evidence of superiority; furthermore, a minimum 24-hour sildenafil washout (or 48-hour tadalafil washout) is required before starting riociguat, and the proposed escalation step is addition of a third pathway agent, not a swap within the NO-cGMP pathway.
Option D: Option D is incorrect because de-escalating ambrisentan and adding a diuretic is not an escalation strategy and would likely worsen rather than improve risk status; diuretics manage volume but do not target the three vasoactive pathways driving disease progression.
Option E: Option E is incorrect because repeat invasive right heart catheterization is not required before escalation in this setting; the 2022 ESC/ERS algorithm allows escalation decisions to be based on the non-invasive and minimally invasive composite parameters of the three-strata model; invasive hemodynamics at every reassessment are not mandated.
6. A 68-year-old woman with known heart failure with preserved ejection fraction (HFpEF) is referred to a pulmonary hypertension clinic after echocardiography estimated her right ventricular systolic pressure at 58 mmHg. The referring cardiologist's note requests initiation of ambrisentan. Before prescribing any PAH-specific therapy, right heart catheterization (RHC) is performed. The results show: mPAP 38 mmHg, PAWP 22 mmHg, cardiac output 4.2 L/min, PVR 1.8 Wood units. What do these hemodynamic findings indicate, and what is the appropriate management?
A) These findings confirm WHO Group 1 PAH because the mPAP exceeds 20 mmHg; ambrisentan should be initiated as requested because lowering pulmonary pressures will reduce right ventricular afterload and improve both right and left heart function
B) These findings confirm WHO Group 2 pulmonary hypertension (postcapillary disease from left heart disease) because the PAWP of 22 mmHg exceeds the 15 mmHg threshold; PAH-specific vasodilators including ambrisentan are contraindicated in this patient and should not be prescribed; management should focus on the underlying HFpEF
C) These findings are indeterminate because the mPAP is above 20 mmHg but the PVR is below 2 Wood units; the correct next step is to repeat RHC after 3 months of empirical ambrisentan to assess whether the PVR rises into the diagnostic range
D) These findings suggest Group 4 CTEPH because the mPAP is elevated without significant PVR elevation; riociguat should be initiated based on its CTEPH approval without further imaging workup
E) These findings are consistent with Group 1 PAH with a concomitant left-sided filling abnormality; initiating a PDE-5 inhibitor rather than an ERA is appropriate because sildenafil selectively reduces pulmonary vascular resistance without worsening left-sided filling pressures in this mixed-mechanism disease
ANSWER: B
Rationale:
The hemodynamic profile — mPAP 38 mmHg, PAWP 22 mmHg, PVR 1.8 Wood units — defines WHO Group 2 postcapillary pulmonary hypertension from left heart disease. The key diagnostic criterion is the PAWP of 22 mmHg, which far exceeds the 15 mmHg threshold that separates precapillary from postcapillary pulmonary hypertension. In Group 2 disease, the elevated mPAP reflects backward transmission of elevated left-sided filling pressures rather than intrinsic pulmonary arterial pathology; the PVR of 1.8 Wood units below the 2 Wood units threshold confirms that there is no significant intrinsic pulmonary vascular resistance elevation. This patient has the pulmonary hypertension of HFpEF — a WHO Group 2 condition for which PAH-specific vasodilators are not only ineffective but potentially harmful. Prescribing ambrisentan (or any prostacyclin, ERA, PDE-5 inhibitor, or sGC stimulator) would selectively dilate the pulmonary vasculature, increase pulmonary blood flow into an already congested left ventricle unable to accommodate increased preload, worsen pulmonary edema, and risk hemodynamic deterioration. Management should address the underlying HFpEF with guideline-directed therapy.
Option A: Option A is incorrect because the PAWP of 22 mmHg categorically excludes Group 1 PAH regardless of the mPAP value; Group 1 PAH requires PAWP at or below 15 mmHg by definition, and prescribing ambrisentan in Group 2 is potentially harmful.
Option C: Option C is incorrect because the findings are not indeterminate — they clearly define Group 2 disease; empirical ambrisentan in Group 2 is contraindicated, not a diagnostic maneuver.
Option D: Option D is incorrect because CTEPH diagnosis requires evidence of chronic thromboembolic disease on CT pulmonary angiography or ventilation-perfusion scanning; elevated mPAP alone does not indicate CTEPH, and the PVR below 2 Wood units is inconsistent with hemodynamically significant CTEPH.
Option E: Option E is incorrect because both ERAs and PDE-5 inhibitors are contraindicated in Group 2 disease; no currently approved PAH vasodilatory agent has demonstrated benefit in HFpEF-associated pulmonary hypertension, and clinical trials of PDE-5 inhibitors in HFpEF have shown neutral or harmful results.
7. A 55-year-old man with WHO Group 1 PAH on an oral ERA plus PDE-5 inhibitor combination has been escalated to add subcutaneous treprostinil infusion eight weeks ago. He presents requesting to stop the subcutaneous infusion due to severe, persistent erythema, induration, and burning pain at all attempted infusion sites, which has significantly impaired his sleep and quality of life. He has no central venous access. He does not have interstitial lung disease. Which route change is most appropriate and pharmacologically justified?
A) Switch to inhaled iloprost six to nine times daily, as it eliminates infusion site pain entirely and provides equivalent prostacyclin receptor coverage to treprostinil with a similar tolerability profile at inhalation doses
B) Switch to oral extended-release treprostinil, as the oral route eliminates all infusion-site adverse effects and gastrointestinal tolerability is generally excellent in patients who tolerated subcutaneous treprostinil for eight weeks
C) Discontinue treprostinil entirely and add selexipag, as persistent subcutaneous intolerance indicates that all prostacyclin-pathway agents will be poorly tolerated due to the shared IP receptor mechanism; selexipag targets the same receptor with a non-prostanoid structure
D) Switch to inhaled treprostinil (Tyvaso) four times daily, as it uses the same active molecule, eliminates infusion site pain without requiring central venous access, is approved for WHO Group 1 PAH, and delivers drug preferentially to ventilated lung regions
E) Place a tunneled central venous catheter for intravenous treprostinil, as this is the only clinically acceptable alternative when subcutaneous intolerance is documented; the IV route provides superior bioavailability and more predictable hemodynamic response than inhaled treprostinil
ANSWER: D
Rationale:
Inhaled treprostinil is the most appropriate route change for this patient. It uses the identical active molecule as subcutaneous treprostinil, providing pharmacological continuity in prostacyclin receptor (IP receptor) agonism, which simplifies dosing conversion and avoids re-titration from a different drug class. The inhalation route completely eliminates infusion site pain — the limiting adverse effect — because no catheter or subcutaneous needle is involved. No central venous access is required, which removes the catheter-related bloodstream infection risk associated with IV treprostinil. Inhaled treprostinil (Tyvaso) is approved for WHO Group 1 PAH (as well as Group 3b PH-ILD), making it pharmacologically and regulatorily appropriate for this patient. It is dosed four times daily by nebulization and preferentially delivers drug to ventilated pulmonary regions, potentially optimizing ventilation-perfusion matching.
Option A: Option A is incorrect because iloprost has a plasma half-life of approximately 20 to 30 minutes requiring six to nine inhalations daily — a substantially more burdensome schedule than inhaled treprostinil's four-times-daily regimen — and its efficacy for Group 1 PAH monotherapy or as add-on is less well established than inhaled treprostinil; while it eliminates infusion site pain, it is not the optimal choice here.
Option B: Option B is incorrect because oral extended-release treprostinil carries a higher gastrointestinal adverse effect burden than parenteral and inhaled routes, including nausea, diarrhea, and abdominal cramping; "generally excellent tolerability" does not accurately characterize the oral formulation, and it is not the preferred route change for subcutaneous intolerance.
Option C: Option C is incorrect because subcutaneous infusion site intolerance is a local skin reaction to the catheter and infusion solution rather than a systemic IP receptor–mediated adverse effect; it does not predict intolerance to all prostacyclin-pathway agents, and discontinuing prostacyclin therapy entirely in favor of selexipag abandons an established add-on therapy without clinical justification.
Option E: Option E is incorrect because IV treprostinil requires tunneled central venous catheter placement, which carries catheter-related bloodstream infection risk; this invasive step is not indicated when a non-invasive inhaled route of the same drug is available and appropriate for the patient's indication.
8. A 29-year-old woman with idiopathic PAH demonstrated a positive acute vasodilator response at diagnosis and was started on high-dose diltiazem 360 mg daily. At six months she was WHO-FC II with a 6MWD of 460 meters and near-normal pulmonary hemodynamics. Now, 18 months into therapy, she presents with progressive exertional dyspnea, WHO-FC III symptoms, a 6MWD of 285 meters, and NT-proBNP of 780 ng/L. Right heart catheterization shows mPAP 42 mmHg and PVR 5.1 Wood units. What is the correct interpretation and management?
A) This patient has lost her sustained vasodilator response to calcium channel blocker (CCB) therapy — a recognized phenomenon in a subset of initially vasoreactive patients; CCB therapy has failed and she requires transition to PAH-specific combination therapy with an ERA plus a PDE-5 inhibitor, with urgent consideration of whether her current risk profile warrants adding a prostacyclin agent
B) The clinical deterioration represents natural disease progression unrelated to treatment; diltiazem should be continued at the current dose and a diuretic added for symptomatic management; the initial vasoreactivity response guarantees continued hemodynamic benefit from CCBs indefinitely
C) The appropriate response is to increase the diltiazem dose to 480 mg daily, as the initial positive response confirms sustained vasoreactivity and the deterioration likely reflects underdosing rather than loss of response
D) She should be switched from diltiazem to nifedipine, as loss of CCB response to diltiazem specifically indicates receptor tachyphylaxis to the benzothiazepine class that does not extend to the dihydropyridine class; nifedipine typically restores hemodynamic response
E) The deterioration indicates development of a concomitant autoimmune connective tissue disease as the new driver of pulmonary hypertension; repeat right heart catheterization should be deferred for 6 months while serological workup is completed before any change in PAH therapy
ANSWER: A
Rationale:
A positive acute vasodilator response at diagnosis qualifies a patient for high-dose CCB therapy as first-line monotherapy, and sustained responders have an excellent prognosis. However, a critical clinical point is that sustained vasodilatory response must be demonstrated at follow-up — typically 3 to 6 months after starting CCB therapy — and is not guaranteed indefinitely. This patient had a documented period of good CCB response (6-month data showing WHO-FC II, favorable 6MWD and hemodynamics), but her current presentation — WHO-FC III, 6MWD 285 meters, NT-proBNP 780 ng/L, mPAP 42 mmHg, and PVR 5.1 Wood units — demonstrates clear hemodynamic and functional deterioration indicating loss of sustained CCB response. This is a recognized phenomenon in a subset of initially vasoreactive patients. When CCB response is lost, the patient must be reclassified as non-vasoreactive for management purposes and transitioned to PAH-specific combination therapy — an ERA plus a PDE-5 inhibitor at minimum — with urgent risk stratification to determine whether a prostacyclin agent is also required given the intermediate-to-high risk hemodynamic profile.
Option B: Option B is incorrect because CCB therapy has objectively failed given the hemodynamic and functional data; a positive initial vasoreactivity response does not guarantee indefinite CCB benefit, and continuing diltiazem while only adding a diuretic would leave the patient on inadequate therapy during disease progression.
Option C: Option C is incorrect because the dose-escalation strategy is not supported by evidence of loss of response; the current hemodynamic data — PVR 5.1 Wood units, mPAP 42 mmHg — confirm that calcium channel blockade is no longer achieving adequate pulmonary vasodilation, and higher diltiazem doses carry risks of negative inotropy and systemic hypotension.
Option D: Option D is incorrect because loss of CCB response does not selectively occur within one CCB subclass while sparing others; it reflects disease progression beyond the reversibility that CCBs can address, and switching to nifedipine would not restore hemodynamic control when diltiazem at therapeutic doses has failed.
Option E: Option E is incorrect because waiting 6 months for autoimmune serological workup before changing PAH therapy is inappropriate when the patient has objective hemodynamic evidence of treatment failure and intermediate-to-high risk parameters; autoimmune evaluation can proceed in parallel with PAH therapy escalation, not as a prerequisite.
9. A 50-year-old man with WHO Group 1 PAH has been on macitentan 10 mg daily for six months as part of dual oral combination therapy. Routine monitoring reveals hemoglobin 9.8 g/dL, down from 13.1 g/dL at baseline. His reticulocyte count is 1.1 percent (normal), mean corpuscular volume (MCV) is 88 fL (normal), white blood cell count and platelet count are normal, he has no symptoms of anemia, and his PAH is clinically well-controlled. What is the most appropriate interpretation and management of this finding?
A) This degree of hemoglobin reduction indicates macitentan-induced bone marrow suppression; macitentan must be discontinued immediately and a bone marrow biopsy performed to exclude aplastic anemia before considering an alternative ERA
B) This hemoglobin pattern is consistent with iron deficiency anemia caused by macitentan-induced hepcidin upregulation; serum ferritin and transferrin saturation should be checked and oral iron supplementation started empirically while awaiting results
C) This is a drug reaction requiring immediate ERA class switch to ambrisentan; the hemoglobin reduction indicates idiosyncratic erythrocyte membrane toxicity unique to the dual ETA/ETB blocking profile of macitentan that does not occur with selective ETA agents
D) This hemoglobin reduction indicates immune-mediated hemolytic anemia; a direct Coombs test and peripheral blood smear should be ordered immediately and macitentan discontinued pending results
E) This hemoglobin reduction is consistent with the recognized macitentan-associated hemodilutional anemia, occurring in approximately 8 percent of patients and caused by plasma volume expansion from vasodilation rather than true erythrocyte loss or marrow failure; the normal reticulocyte count and MCV support hemodilution; no dose change or drug discontinuation is required, and the patient should be monitored with serial hemoglobin checks
ANSWER: E
Rationale:
Hemoglobin reduction occurs in approximately 8 percent of patients treated with macitentan and is a recognized, expected drug effect attributed to plasma volume expansion from the drug's potent vasodilatory action. Vasodilation lowers systemic vascular resistance, triggers compensatory fluid retention through the renin-angiotensin-aldosterone system, and expands plasma volume — diluting the red cell mass and reducing measured hemoglobin concentration without reducing total erythrocyte number or impairing erythropoiesis. The laboratory pattern consistent with hemodilution is precisely what this patient shows: hemoglobin reduction with a normal reticulocyte count (confirming intact marrow output with no anemia stimulus), normal MCV (excluding iron deficiency or folate/B12 deficiency), and normal white cell and platelet counts (excluding global marrow suppression). The patient is asymptomatic and his PAH is well-controlled. The appropriate management is observation with serial hemoglobin monitoring rather than dose change or drug discontinuation.
Option A: Option A is incorrect because bone marrow suppression from macitentan is not a recognized mechanism of its hemoglobin effect; marrow suppression would produce a reduced reticulocyte count and likely pancytopenia, neither of which is present here; biopsy is not indicated.
Option B: Option B is incorrect because iron deficiency anemia would produce a low MCV and reduced serum ferritin; the normal MCV here excludes microcytic iron deficiency, and macitentan does not cause iron deficiency through hepcidin upregulation.
Option C: Option C is incorrect because idiosyncratic erythrocyte membrane toxicity is not a recognized macitentan adverse effect; hemodilution, not erythrocyte destruction, is the mechanism, and switching to ambrisentan is not indicated for a recognized and manageable drug effect.
Option D: Option D is incorrect because immune-mediated hemolytic anemia would produce an elevated reticulocyte count (compensatory marrow response to red cell destruction), indirect hyperbilirubinemia, and low haptoglobin — not the normal reticulocyte count and MCV seen here; macitentan is not associated with Coombs-positive hemolysis.
10. A 44-year-old woman with WHO Group 1 PAH is on macitentan plus sildenafil 20 mg three times daily. The PAH team decides to switch the NO-pathway component from sildenafil to riociguat due to suboptimal response. She tolerates sildenafil's current dose without significant adverse effects. Which transition plan is pharmacologically correct?
A) Stop sildenafil and start riociguat 2.5 mg three times daily on the same day; no washout is needed because riociguat raises cGMP through production while sildenafil raises it through reduced breakdown — the mechanisms are complementary rather than additive once riociguat is titrated gradually
B) Stop both macitentan and sildenafil simultaneously; restart macitentan after a 48-hour washout; start riociguat 1.0 mg three times daily after macitentan is re-established; this two-stage washout prevents hypotension from any residual ERA-sildenafil-riociguat triple interaction
C) Stop sildenafil and observe a minimum 24-hour washout before starting riociguat 1.0 mg three times daily; macitentan should be continued uninterrupted throughout the transition; riociguat is then up-titrated by 0.5 mg per dose at 2-week intervals to the maximum tolerated dose with blood pressure monitoring at each step
D) Overlap sildenafil and riociguat for 72 hours during the transition to prevent any gap in NO-pathway coverage; gradually reduce the sildenafil dose over this period while riociguat is increased; macitentan is held during the overlap to reduce the total vasodilatory load
E) Stop sildenafil and observe a minimum 7-day washout before starting riociguat to ensure complete elimination of sildenafil and its active metabolite; macitentan should also be held during the washout to minimize hypotension risk during the period of absent NO-pathway coverage
ANSWER: C
Rationale:
The transition from sildenafil to riociguat requires careful management of the absolute contraindication between PDE-5 inhibitors and riociguat. Sildenafil inhibits PDE-5 to prevent cGMP breakdown while riociguat stimulates sGC to produce more cGMP; combined use produces additive cGMP accumulation causing severe hypotension. The required washout for sildenafil — which has a plasma half-life of approximately 4 hours — is a minimum of 24 hours before riociguat initiation, ensuring that clinically meaningful PDE-5 inhibition from sildenafil has resolved before cGMP production is stimulated by riociguat. During this transition, macitentan should be continued uninterrupted because there is no pharmacodynamic interaction between ERAs and riociguat, and interrupting ERA therapy risks loss of endothelin pathway suppression. Riociguat is initiated at 1.0 mg three times daily — the standard starting dose — and up-titrated by 0.5 mg per dose at 2-week intervals to the maximum tolerated dose (maximum 2.5 mg three times daily) with blood pressure monitoring at each titration step.
Option A: Option A is incorrect because starting riociguat on the same day as stopping sildenafil does not allow adequate washout; residual sildenafil PDE-5 inhibition persists for hours after the last dose, and concurrent riociguat would produce additive cGMP accumulation during the overlap period.
Option B: Option B is incorrect because macitentan does not require washout before starting riociguat — ERAs and sGC stimulators are pharmacodynamically compatible; stopping macitentan adds unnecessary complexity and risks loss of endothelin pathway control during the transition.
Option D: Option D is incorrect because overlapping sildenafil and riociguat even at reduced doses is absolutely contraindicated; partial dose overlap does not eliminate the additive cGMP interaction risk.
Option E: Option E is incorrect because a 7-day washout for sildenafil is far longer than required given its 4-hour half-life; the minimum established washout is 24 hours, and holding macitentan during the washout is not indicated or beneficial.
11. A 67-year-old man is diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) following recurrent pulmonary emboli. Multidisciplinary team review determines he is inoperable due to technically inaccessible distal thrombus location and significant comorbidities that preclude cardiopulmonary bypass. He has no prior PAH therapy. Which pharmacological treatment has a specific regulatory approval for this indication, and on what trial evidence is that approval based?
A) Macitentan, based on the SERAPHIN trial demonstrating a 45 percent reduction in the morbidity-mortality composite endpoint in patients with inoperable CTEPH enrolled alongside WHO Group 1 PAH patients in the same trial
B) Riociguat, based on the CHEST-1 trial (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase Stimulator Trial 1) which demonstrated significant improvements in 6MWD, pulmonary hemodynamics, and time to clinical worsening in patients with inoperable CTEPH or recurrent/persistent CTEPH after pulmonary endarterectomy; riociguat is the only approved PAH vasodilatory agent with a WHO Group 4 indication
C) Selexipag, based on the GRIPHON trial which enrolled patients with both WHO Group 1 PAH and WHO Group 4 CTEPH and demonstrated a 40 percent reduction in composite morbidity-mortality events across both groups equally
D) Bosentan, based on the BREATHE-4 trial specifically designed for CTEPH patients, which demonstrated sufficient efficacy to support its formal regulatory approval for inoperable CTEPH as a first-line agent
E) Sildenafil, based on the SUPER-1 trial which included a CTEPH subgroup analysis demonstrating significant 6MWD improvement sufficient to support an FDA supplemental approval for Group 4 disease in patients ineligible for surgery
ANSWER: B
Rationale:
Riociguat is the only approved PAH vasodilatory agent with a regulatory indication for chronic thromboembolic pulmonary hypertension (WHO Group 4). This approval is based on the CHEST-1 trial, which enrolled patients with either inoperable CTEPH or recurrent or persistent CTEPH following pulmonary endarterectomy and demonstrated a significant 39-meter improvement in 6MWD as the primary endpoint, along with significant improvements in pulmonary vascular resistance, NT-proBNP, WHO functional class, and time to clinical worsening compared with placebo. The mechanistic rationale is riociguat's NO-independent sGC stimulation, which generates cGMP in the remodeled CTEPH vasculature where endothelial NO production is severely impaired — a state that limits the efficacy of agents entirely dependent on residual NO signaling. For this patient, riociguat initiated at 1.0 mg three times daily and titrated to maximum tolerated dose (up to 2.5 mg three times daily) is the pharmacologically and regulatorily appropriate choice.
Option A: Option A is incorrect because SERAPHIN enrolled exclusively WHO Group 1 PAH patients and macitentan does not hold a CTEPH indication; SERAPHIN demonstrated benefit in PAH but the evidence base and label do not extend to WHO Group 4.
Option C: Option C is incorrect because GRIPHON enrolled exclusively WHO Group 1 PAH patients; selexipag has no CTEPH enrollment or approval, and the 40 percent morbidity-mortality reduction from GRIPHON applies only to Group 1 disease.
Option D: Option D is incorrect because while the BREATHE-4 trial explored bosentan in CTEPH patients, it did not produce results sufficient to support a formal regulatory approval for CTEPH; bosentan's approved indications do not include WHO Group 4 CTEPH.
Option E: Option E is incorrect because SUPER-1 enrolled WHO Group 1 PAH patients only; sildenafil does not hold an FDA approval for CTEPH, and a subgroup analysis from a Group 1 trial is not the basis for a CTEPH indication.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.